MARKET

SRTS

SRTS

Sensus Hlthcr
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.410
-0.030
-1.23%
Closed 16:00 04/02 EDT
OPEN
2.590
PREV CLOSE
2.440
HIGH
2.590
LOW
2.410
VOLUME
11.61K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
2.102
MARKET CAP
39.73M
P/E (TTM)
-23.0622
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRTS stock price target is 7.75 with a high estimate of 10.00 and a low estimate of 5.50.

EPS

SRTS News

More
  • Stratus Properties, Inc. to Host Earnings Call
  • ACCESSWIRE · 03/16 14:00
  • Sensus Healthcare Highlights Publication Of Research On Long-Term Efficacy, Safety Of Superficial Radiation Therapy In 'Journal Of Drugs In Dermatology'
  • Benzinga · 03/03 13:39
  • Sensus Healthcare Announces Publication of Research on Long-term Efficacy and Safety of Superficial Radiation Therapy in Journal of Drugs in Dermatology
  • GlobeNewswire · 03/03 13:30
  • Edited Transcript of SRTS earnings conference call or presentation 13-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 02/28 12:38

Industry

Advanced Medical Equipment & Technology
+4.07%
Healthcare Equipment & Supplies
+3.32%

Hot Stocks

Symbol
Price
%Change

About SRTS

Sensus Healthcare, Inc., formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment. The Company's product, the SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions that would otherwise be difficult or require surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth and the lining of the ear.
More

Webull offers kinds of Sensus Healthcare Inc stock information, including NASDAQ:SRTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRTS stock news, and many more online research tools to help you make informed decisions.